Neovasc Inc. (NVCN)
NASDAQ: NVCN
· Real-Time Price · USD
30.03
0.00 (0.00%)
At close: Apr 10, 2023, 10:00 PM
Company Description
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally.
Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.
The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008.
Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Neovasc Inc.
| Country | CA |
| IPO Date | May 23, 2001 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Fredericus A. Colen |
Contact Details
Address: 13562 Maycrest Way Richmond, BC CA | |
| Website | https://www.neovasc.com |
Stock Details
| Ticker Symbol | NVCN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001399708 |
| CUSIP Number | 64065J304 |
| ISIN Number | CA64065J3047 |
| Employer ID | 00-0000000 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Fredericus A. Colen | Pres, Chief Executive Officer & Director |
| Christopher Clark B.A., BA (Honours), C.A., CA, PgD | Chief Financial Officer & Corporation Sec. |
| William Reed Little | Chief Operating Officer |
| John Christopher Panton | Chief Quality Officer |
| Sarah Marie-Hodgson Gallagher | Vice President of Clinical Affairs |
| Susan Milne | Vice President of HR |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2023 | 15F-12B | Filing |
| Apr 12, 2023 | 6-K | Filing |
| Apr 11, 2023 | 6-K | Filing |
| Apr 11, 2023 | RW | Filing |
| Apr 11, 2023 | F-10POS | Filing |
| Apr 11, 2023 | POS AM | Filing |
| Apr 11, 2023 | S-8 POS | Filing |
| Apr 11, 2023 | 25-NSE | Filing |
| Apr 11, 2023 | 6-K | Filing |
| Mar 31, 2023 | 6-K | Filing |